Tamtam Try Tamtam free
Labcorp logo

Labcorp account plan

Global laboratory services leader

At a glance

Labcorp is a global laboratory services company with nearly 71,000 employees and FY2025 revenue of $13,951.7 million, performing more than 750 million tests.

Labcorp Holdings, headquartered in Burlington, North Carolina, provides diagnostic testing to physicians, hospitals, health systems, payers and consumers, and laboratory services to pharmaceutical, biotechnology and diagnostic companies. In 2025 it performed more than 750 million tests, served clients in approximately 100 countries and supported more than 85% of the new drugs and therapeutic products approved by the FDA. FY2025 revenue was $13,951.7 million (+7.2%), operating income $1,384.7 million and net earnings attributable to Labcorp $876.5 million (diluted EPS $10.46). North America accounted for 87% of revenue. It has nearly 71,000 employees and is led by Chairman and CEO Adam Schechter.

Business units

Strategic priorities

Lead in specialty testing
Labcorp targets oncology, neurology, autoimmune diseases and women's health; specialty testing grows about three times faster than the broader diagnostics market. Recent launches include the FDA-cleared Elecsys pTau-217 Alzheimer's blood test and an FDA-approved companion diagnostic for advanced melanoma.
Partner of choice for health systems and pharma
Labcorp signed or completed 13 collaboration transactions with health systems and local or regional labs in 2025; deals must be accretive in the first year and return the cost of capital by year three.
Personalized health solutions
Labcorp OnDemand offers over 140 panels and tests, including the Marker by Labcorp Genetic Health Panel, and the MyLabcorp AI-powered app has been downloaded by millions of consumers.
Advanced technology
Investor Day named AI and robotics as a priority; technology work covers Test Finder, laboratory robotics, digital pathology and the next generation of Labcorp Global Trial Connect.
Long-term financial outlook through 2029
Compound annual revenue growth of 5% to 8%, adjusted EPS growth of 8.5% to 11.5% and adjusted operating margin expansion of 75 to 150 basis points by the end of 2029.
LaunchPad savings
The LaunchPad program is on track for $125 million of savings in 2026 and is being accelerated to offset PAMA reimbursement cuts.

Latest results

In Q3 2026 (quarter ended September 30, 2026) revenue rose 6.9% to $3,810.0 million, with organic growth of 5.5%. Adjusted operating income was $570.0 million (15.0% margin, +60 bp), adjusted EPS $4.78 (+14.5%) and free cash flow $412.2 million, while GAAP operating income rose 1.4% to $402.1 million as LaunchPad and acquisition-related corporate costs increased. BLS grew 9.6% organically with a TTM book-to-bill of 1.10. Labcorp raised its 2026 guidance to revenue of $14,779-$14,887 million (+5.9% to 6.7%) and adjusted EPS of $18.30-$18.70, keeping free cash flow at $1,240-$1,360 million.

Investments and deals

BioReference Health assets
Agreement of October 15, 2026 with OPKO Health to acquire select BioReference Health assets, including the 4Kscore prostate cancer test, for up to $872.0 million, expected to close mid-2027.
Myriad Prenatal Health and Millennium Health
Agreements in October 2026 to acquire Myriad Genetics' Prenatal Health business for approximately $210.0 million and drug testing laboratory Millennium Health for up to $375.0 million.
2026 acquisitions completed
Nine-month 2026 acquisitions totalled $789.1 million, including Empire City Laboratories, Parkview Health outreach assets and MLM Medical Labs, which gives Labcorp a wholly owned central lab network across four continents.
Capex and new facilities
Capex is planned at nearly 4% of revenue in 2026, for core growth, facility expansion, LaunchPad and integration; a new Central Lab facility is under construction in Indianapolis.
SYNLAB minority stake
A 15% minority interest in SYNLAB was acquired for approximately $151.6 million, closed March 2025, as a step toward global reach.

Challenges and risks

PAMA reimbursement cuts
Rate decreases are frozen for 2026 but resume in 2027, capped at 15% per year for 2027 to 2029; Labcorp's base case assumes about $125 million of impact in 2027.
Payer utilization controls
Prior authorization, laboratory benefit management programs, narrow networks and claims edits weigh on molecular, genetic and toxicology testing; ACA exchange changes cost about 30 basis points of Dx volume in Q3 2026.
Biopharma R&D dependence
BLS revenue depends on pharma, biotech and medical device R&D spending; Early Development was restructured in 2025, with $105.5 million of charges.
ERP rollout and technology risk
A new risk factor covers extending a new ERP system across the company, which could disrupt supply chain, procurement and transaction processing; cybersecurity and AI risks are also named.
Refinancing at higher rates
Labcorp expects to refinance its $600.0 million 3.60% senior notes due September 2027 at higher interest rates.

What leadership says

“Labcorp has never been more relevant than it is today”

Adam Schechter, Chairman and CEO · 2026 Investor Day press release, September 10, 2026

“We are disappointed by the recent announcement on the proposed fee schedule changes related to PAMA”

Adam Schechter, Chairman and CEO · Q3 2026 earnings call, October 28, 2026

“Our confidence in this outlook is grounded in a proven record of delivering on our commitments and a disciplined value creation framework that converts growth into earnings, cash flow and shareholder returns”

Julia Wang, Executive Vice President and CFO · 2026 Investor Day press release, September 10, 2026

“The market typically grows at 1%-2%, so we're growing substantially more than the overall market”

Adam Schechter, Chairman and CEO · Q2 2026 earnings call, July 30, 2026

Where a supplier can help

Acquisition integration
With BioReference, Myriad Prenatal Health and Millennium Health pending after $789.1 million of 2026 deals, Labcorp needs integration support across labs, patient service centers, billing and IT.
Automation and robotics
AI and robotics are a stated priority and LaunchPad savings are being accelerated against PAMA cuts; lab automation, robotics and workflow vendors fit both.
ERP and procurement transformation
The company-wide ERP extension is a named risk; implementation partners, data migration and change-management services can reduce disruption.
Revenue cycle and payer management
Reimbursement pressure and utilization controls such as prior authorization create demand for revenue cycle, claims and payer analytics tools.
Clinical trial technology and logistics
BLS is growing with a new Indianapolis Central Lab facility and Global Trial Connect enhancements; trial logistics, kit supply and sponsor portal technology providers can support that growth.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Labcorp?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Labcorp

What does Labcorp do?

Labcorp runs diagnostic laboratories serving physicians, health systems, payers and consumers, and provides central laboratory and early development services to biopharma companies; it performed more than 750 million tests in 2025.

What is Labcorp's revenue?

FY2025 revenue was $13,951.7 million, up 7.2%. For 2026 Labcorp guides revenue of $14,779-$14,887 million.

How many employees does Labcorp have?

Labcorp has nearly 71,000 employees serving clients in approximately 100 countries.

What is Labcorp's strategy?

Four priorities: lead in specialty testing, be a partner of choice for health systems and pharma, drive personalized health solutions, and use advanced technology including AI and robotics.

Who leads Labcorp?

Adam Schechter is Chairman and CEO, and Julia Wang is Executive Vice President and CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)